Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
8 studies found for:    "Primary carnitine deficiency"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Identification of Carnitine-Responsive Cardiomyopathy
Condition: Carnitine Deficiency
Intervention: Drug: Carnitine
2 Completed Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides
Condition: Carnitine Transporter Deficiency
Intervention: Other: Fasting blood and urine collection
3 Completed Fat and Sugar Metabolism During Exercise, With and Without L-carnitine in Patients With Carnitine Transporter Deficiency
Condition: Carnitine Transporter, Plasma-membrane, Deficiency of
Intervention: Dietary Supplement: Break in L-carnitine treatment
4 Recruiting Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
Conditions: Prematurity;   Neurodevelopmental Disorder;   Carnitine Deficiency
Interventions: Drug: L-carnitine;   Drug: 5% Dextrose
5 Completed Carnitine Levels and Carnitine Supplementation in Type I Diabetes
Conditions: Diabetes Mellitus, Type I;   Hypoglycemia
Intervention: Drug: Carnitine (drug)
6 Completed L-Carnitine to Treat Fatigue in AIDS Patients
Conditions: HIV Infections;   AIDS
Interventions: Drug: L-carnitine;   Other: Placebo
7 Recruiting Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy
Conditions: Metabolism, Inborn Errors;   Lipid Metabolism, Inborn Errors;   Carbohydrate Metabolism, Inborn Errors;   Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency;   Glycogenin-1 Deficiency (Glycogen Storage Disease Type XV);   Carnitine Palmitoyl Transferase 2 Deficiency;   VLCAD Deficiency;   Medium-chain Acyl-CoA Dehydrogenase Deficiency;   Multiple Acyl-CoA Dehydrogenase Deficiency;   Carnitine Transporter Deficiency;   Neutral Lipid Storage Disease;   Glycogen Storage Disease Type II;   Glycogen Storage Disease Type III;   Glycogen Storage Disease Type IV;   Glycogen Storage Disease Type V;   Muscle Phosphofructokinase Deficiency;   Phosphoglucomutase 1 Deficiency;   Phosphoglycerate Mutase Deficiency;   Phosphoglycerate Kinase Deficiency;   Phosphorylase Kinase Deficiency;   Beta Enolase Deficiency;   Lactate Dehydrogenase Deficiency;   Glycogen Synthase Deficiency
Intervention: Other: Sugar
8 Completed
Has Results
Levocarnitine in Treating Fatigue in Cancer Patients
Conditions: Fatigue;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: levocarnitine;   Other: placebo

Study has passed its completion date and status has not been verified in more than two years.